Although the chemo‐immunotherapy adjuvanted with Toll‐like receptor 7/8 agonist (TLR 7/8a) induces immunogenic cell death (ICD) and in situ vaccination effect, indoleamine 2,3‐dioxygenase (IDO) is also significantly increased in the tumor microenvironment (TME) and tumor‐draining lymph node (TDLN), which offsets the activated antitumor immunity. Here, IDO1 is linked to neoplasm.